Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia
Viruses · 2023
DOI: 10.3390/v15040844 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Viruses, 2023. Verfasst von Jolene Yin Ling Fu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education, Malaysia, Universiti Malaya.
Abstract (Originalsprache)
Vaccine efficacy against SARS-CoV-2 could be compromised by the emergence of SARS-CoV-2 variants and it is important to study how it impacts the booster vaccination regime. We investigated the humoral and T cell responses longitudinally in vaccinated uninfected (n = 25) and post-COVID-19 individuals (n = 8), and those who had received a BNT162b2 booster following complete two-doses regimes of either BNT162b2 (homologous) (n = 14) or ChAdOx1-S (heterologous) (n = 15) vaccines, by means of a SARS-CoV-2 pseudovirus neutralization test and QuantiFERON SARS-CoV-2 assay. Vaccinated post-COVID-19 individuals showed higher neutralizing antibodies with longer durability against SARS-CoV-2 wild type (WT) and Omicron spikes, but demonstrated similar declining T cell responses compared to the uninfected vaccinated. Two doses of BNT162b2 induced higher neutralizing antibodies against WT and T cell responses than ChAdOx1-S for six months. The BNT162b2 booster confers a greater humoral response against WT, but a similar cross-neutralizing antibody against Omicron and T cell responses in the homologous booster group compared to the heterologous booster group. Breakthrough infection in the homologous booster group (n = 11) significantly increased the neutralizing antibody, but T cell responses remained low. Our data may impact government public health policy regarding the administration of mix-and-match vaccines, where both vaccination regimes can be employed should there be shortages of certain vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia.
- Department of Medical Microbiology, University Malaya Medical Centre, Kuala Lumpur 59100, Malaysia.
ORCID-Profile: Jolene Yin Ling Fu, Yoke Fun Chan
Förderung
- Ministry of Higher Education, Malaysia
- Universiti Malaya
Zitieren
APA
Fu, J. Y. L., Pukhari, M. H., Bador, M. K., Sam, I. C., & Chan, Y. F. (2023). Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia. Viruses. https://doi.org/10.3390/v15040844
Vancouver
Fu JYL, Pukhari MH, Bador MK, Sam IC, Chan YF. Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia. Viruses. 2023. doi:10.3390/v15040844
BibTeX
@article{Fu2023,
author = {Fu, Jolene Yin Ling and Pukhari, Muhammad Harith and Bador, Maria Kahar and Sam, I-Ching and Chan, Yoke Fun},
title = {Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15040844}
}
EUVIMED